Novartis AG(DE:NOT)
€138.38-4.34 (-3.04%)
DE:NOT
Novartis AG stock drug pipeline
€138.38
At close:-4.34 (-3.04%)
Novartis AG (NOT) Drug Pipeline
23 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Novartis (DE:NOT) have in its pipeline
Novartis AG DE:NOT is currently developing the following drugs: Cls12311 Low, Cls12311 Medium, Cls12311 High, Uncoupled Rbcs, Imx-110 Combined With Tislelizumab, Ribociclib, Everolimus, Alpelisib, Palazestrant, Fulvestrant, Alpelisib, Tucatinib, Ketamine, Mrtx849, Tno155, Amg334, Oral Prophylactic, Erenumab, Daratumumab, Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pembrolizumab, Capecitabine, Temozolomide, Pemetrexed, Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Rucaparib, Regorafinib, Enzalutamide, Sunitinib, Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Nivolumab, Ipilimumab, Trametinib, Regorafenib, Ceritinib, T-326 Inhaler, Aggripal®, Pbf-509_80 Mg, Pbf-509_160 Mg, Pbf-509_320 Mg, Pbf-509_640 Mg, Combo Pbf-509 (160 Mg) + Pdr001, Combo Pbf-509 (320 Mg) + Pdr001, Combo Pbf-509 (640 Mg) + Pdr001, Rp2d (Pbf-509+Pdr001)_Immuno Naïve, Experimental: Rp2d (Pbf-509+Pdr001)_Immuno Treated, Ap Booster, Tdap Booster, Licensed Tdap Booster (Boostrix®), N-Acetylcysteine, Meningococcal (Group B) Multicomponent Recombinant Adsorbed Vaccine, Octreotide Fluidcrystal® Injection Depot, Diclofenac Sodium Gel 1%, Carfilzomib, Afuresertib, Rabies Vaccine, Rabies Vaccines + Rabies Immunoglobulins, Rmenb+Omv, Ciprofloxacin (Bayq3939) Dry Powder For Inhalation, Meningococcal B Recombinant Vaccine Rmenb+Omv Nz, Meningococcal Acwy-Crm Conjugate Vaccine, Bps804, Ciprofloxacin Dpi (Bayq3939), Pazopanib, Bkm120, Meningococcal Acwy Conjugate Vaccine, Depiquick Birch (Dpg103), Paracetamol (500 Mg)/Dimethindene Maleate (1 Mg)/ Phenylephrine Hydrochloride (10 Mg) Tablets, Paracetamol (500 Mg) Tablets, Menc-Crm Liq, Menc-Crm Ros, Menc-Crm Emv, Dexamethasone, Bortezomib, Gsk2110183, Bps804 20Mg/Kg, Bct197 Part A, Bct197 Part B, Prednisone, Bct197, Ruxolitinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

